These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26141739)

  • 1. Glatiramer acetate-induced hepatitis in a patient with multiple sclerosis.
    Flaire A; Carra-Dalliere C; Ayrignac X; Blanc P; Labauge P
    Acta Neurol Belg; 2016 Mar; 116(1):99-100. PubMed ID: 26141739
    [No Abstract]   [Full Text] [Related]  

  • 2. Glatiramer acetate during early pregnancy: A prospective cohort study.
    Herbstritt S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
    Mult Scler; 2016 May; 22(6):810-6. PubMed ID: 26754804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection--a case report.
    Zecca C; Mainetti C; Blum R; Gobbi C
    BMC Neurol; 2015 Dec; 15():249. PubMed ID: 26630967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ulnar neuropathy after glatiramer acetate subcutaneous injection: Ultrasound findings.
    Coraci D; Giovannini S; Loreti C; Padua L
    J Clin Pharm Ther; 2019 Feb; 44(1):140-141. PubMed ID: 30315577
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hepatitis induced by glatiramer acetate].
    Fernández Fernández N; Joao Matias D; Pisabarros Blanco C; Rodríguez Martín L; Aparicio Cabezudo M; Linares Torres P; Hernando Martín M; Olcoz Goñi JL
    Gastroenterol Hepatol; 2015 Apr; 38(4):280-1. PubMed ID: 25042243
    [No Abstract]   [Full Text] [Related]  

  • 6. Aseptic meningitis after glatiramer acetate.
    Niessen A; Schwarz B; Urban M; Krämer S; Reinhard M
    J Neurol; 2021 Jul; 268(7):2589-2590. PubMed ID: 33909159
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple sclerosis and glatiramer acetate: Risk factors for central retinal vein occlusion?
    Pascual-Santiago MA; Burgos-Blasco BP; Enríquez-Fuentes JE; Fernandez-Vigo JI
    J Fr Ophtalmol; 2023 Mar; 46(3):235-238. PubMed ID: 36774312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A place of first-line drugs in treatment of multiple sclerosis].
    Kasatkin DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):145-151. PubMed ID: 28635741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. It is safe to switch therapy from interferon beta or glatiramer acetate to oral therapy in patients with relapsing multiple sclerosis with stable disease.
    Koch-Henriksen N
    J Neurol Neurosurg Psychiatry; 2021 May; 92(5):457. PubMed ID: 33563802
    [No Abstract]   [Full Text] [Related]  

  • 10. Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis.
    Drago F; Brusati C; Mancardi G; Murialdo A; Rebora A
    Arch Dermatol; 1999 Oct; 135(10):1277-8. PubMed ID: 10522686
    [No Abstract]   [Full Text] [Related]  

  • 11. Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate.
    Frese A; Bethke F; Lüdemann P; Stögbauer F
    J Neurol; 2000 Sep; 247(9):713. PubMed ID: 11081814
    [No Abstract]   [Full Text] [Related]  

  • 12. Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis.
    Bourdette D; Hartung D
    JAMA Neurol; 2015 Dec; 72(12):1411-3. PubMed ID: 26457848
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of immediate hypersensitivity reaction to glatiramer acetate.
    Amsler E; Autegarden JE; Gaouar H; Frances C; Soria A
    Eur J Dermatol; 2017 Feb; 27(1):92-95. PubMed ID: 27799134
    [No Abstract]   [Full Text] [Related]  

  • 14. Flare-up reaction in the inoculation drug sites by glatiramer acetate: First case described.
    Sánchez-González MJ; Barbarroja-Escudero J; Antolín-Amérigo D; Rodríguez-Rodríguez M; Pericet-Fernández L; Vélez D; Bellón-Heredia T; Alvarez-Mon M
    Allergol Int; 2016 Oct; 65(4):469-471. PubMed ID: 27094120
    [No Abstract]   [Full Text] [Related]  

  • 15. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicolau Syndrome After Glatiramer Acetate Injection in Close Proximity to Administration of SARS-CoV-2 mRNA Vaccine.
    Sy MY; Fromm E; Doan L; Rojek N; Brandt AU
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34759023
    [No Abstract]   [Full Text] [Related]  

  • 17. Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?
    Sørensen PS
    Nat Rev Neurol; 2016 Jan; 12(1):5-6. PubMed ID: 26635211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended use of glatiramer acetate (Copaxone) for MS.
    Greenstein JI
    Neurology; 1999 Mar; 52(4):897-8. PubMed ID: 10078765
    [No Abstract]   [Full Text] [Related]  

  • 19. CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone).
    Losy J; Michałowska-Wender G; Kurdyńska A; Wender M
    Folia Neuropathol; 2005; 43(3):153-5. PubMed ID: 16245210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months.
    Fiore AP; Fragoso YD
    Arq Neuropsiquiatr; 2005 Sep; 63(3B):738-40. PubMed ID: 16258646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.